RBC Affirms Valeant (VRX) at 'Sector Perform'; Q2 Slightly Below Views, Walgreens Derm co-Pay Shows Improvement
- Wall St. lower as earnings from some big names disappoint
- Unusual 11 Mid-Day Movers 10/25: (CWEI) (NXTD) (EYES) Higher; (DPRX) (CRBP) (CALA) Lower (more...)
- General Motors (GM) Tops Q3 EPS by 28c
- Procter & Gamble (PG) Tops Q1 EPS by 5c
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
RBC affirms Valeant (NYSE: VRX) Sector Perform with a price target of $31 following Q2 results on Tuesday.
Analyst Douglas Miehm offered the following quick commentary ahead of the company's conference call:
Total revenues in Q2/16 were $2.42B vs. our forecast of $2.47B, and consensus of $2.47B (FactSet,15 analysts, $2.30-2.66B range). Relative to our forecasts, the Derm, GI, and Neuro/Other segments came in below our expectations, and the Emerging Markets businesses performed better than our expectations. We also note that VRX has sold all North American rights to Ruconest for up to $125MM (upfront $60MM) to Pharming .... Adj. EPS was $1.40 vs. our $1.44 estimate and consensus of $1.47 (FactSet, 18 analysts, $1.20-1.77 range). Management reiterated full-year 2016 guidance of $9.9-10.1B in revenues, Adj. EBITDA of $4.8-4.95B, and Adj. EPS of $6.60-7.00.
Walgreens (Nasdaq: WBA) derm co-pays increased as VRX continues to work through Walgreens ‘speed bumps’. Of note, the co-pays for commercially insured patients for Jublia, Onexton, and Solodyn increase from $0 to $25, and for all other brands that run through Walgreens, the co-pay increases from $35 to $40. The new Walgreens Access Program details include a Commercially Insured and Drug Not Covered patient category. Full details of the new co-pay program are outlined further in the note. We view the changes positively as the company will now receive cash co-payments from all patients, which we believe should resolve the negative ASP issue that plagued the derm portfolio in H1 2016. We also note that Valeant has rolled out the Walgreens access program to other independent pharmacies and based on our preliminary channel checks, it appears that Valeant has signed up a high number of independent pharmacies, with all searched zip codes leading to independent pharmacies outnumbering Walgreens locations by a significant number.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Valeant Pharma (VRX) Moves Off Lows on Bill Miller Comments
- Swift Transportation (SWFT) PT Bumped to $24 at Stifel Following Solid Q3
- UBS Cuts Price Target on V.F. Corp. (VFC) to $59; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!